Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
182 hedge funds and large institutions have $2.47B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 71 increasing their positions, 51 reducing their positions, and 11 closing their positions.
200% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 11
72% more call options, than puts
Call options by funds: $24.4M | Put options by funds: $14.2M
39% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 51
13% more capital invested
Capital invested by funds: $2.18B → $2.47B (+$288M)
13% more funds holding
Funds holding: 161 → 182 (+21)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$28.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.9M |
| 3 |
Goldman Sachs
New York
|
+$14.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$12.1M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$30.8M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$25.2M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$20M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$14.2M |
| 5 |
EP
Eversept Partners
New York
|
-$9.26M |
DCPH Hedge Fund Activity: Q4 2020 in Review
182 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2020, worth a combined $2.47B — up 13% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new DCPH positions and 11 closed out — a net gain of 22 holders — while 71 added to existing stakes and 51 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $28.7M. The largest seller was Avoro Capital Advisors, cutting an estimated $30.8M.
- 182 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2020, up from 161 in Q3 2020.
- Funds reported $2.47B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2020, up 13% quarter-over-quarter.
- 33 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 11 closed out, a net change of +22 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was Consonance Capital Management, an estimated $28.7M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was Avoro Capital Advisors, an estimated $30.8M sold.
Based on aggregated 13F filings for Q4 2020.